Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 17/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 7/20 | 0.54 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | CCNK | O75909 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 3/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 2/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1949578 | 0.88 | CDK9 (0.59) | CDK9CCNT1PIP5K1CPIK3CACCNK | |
| SCHEMBL1463729 | 0.85 | CDK9 (0.75) | CDK9CCNT1 | |
| SCHEMBL1461797 | 0.81 | CCNT1 (0.45) | CDK9CCNT1CCNKCDK2CDK1 | |
| SCHEMBL1947567 | 0.81 | CCNT1 (0.45) | CDK9CCNT1CCNKCDK2CDK1 | |
| SCHEMBL10285489 | 0.80 | CCNT1 (0.57) | CDK9CCNT1CCNK | |
| SCHEMBL1462988 | 0.80 | CCNT1 (0.48) | CDK9CCNT1CCNKCDK2CDK1 | |
| SCHEMBL10285637 | 0.79 | CDK9 (0.48) | CDK9CCNT1PIP5K1CPIK3CACCNK | |
| SCHEMBL10285430 | 0.79 | CCNT1 (0.42) | CDK9CCNT1CCNKCDK2CDK1 | |
| SCHEMBL12820017 | 0.78 | CCNT1 (0.41) | CDK9CCNT1CCNKCDK2CDK1 | |
| SCHEMBL10285644 | 0.76 | CDK9 (0.62) | CDK9CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | NOVARTIS AG (CH) | 2011-06-02 | — | — | US | claimed |
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | NOVARTIS AG (CH) | 2011-06-02 | — | — | US | disclosed |
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | NOVARTIS AG (CH) | 2011-06-02 | — | — | US | disclosed |
| WO-2011026911-A1 | BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | CDK2, CDK1, CDKL1 | CDK9 5/4885CCNT1 47/4885PIP5K1C 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.